MediWound Ltd. Chief Executive Officer Ofer Gonen filed a Form 4 on November 12, 2026, disclosing the exercise of Series A Warrants to acquire 8,168 ordinary shares on November 10, 2026, at an exercise price of $13.475 per share.

Key Highlights

  • Warrant exercise: Ofer Gonen exercised Series A Warrants on November 10, 2026, to purchase 8,168 ordinary shares of MediWound Ltd. at $13.475 per share, with the aggregate exercise price paid in cash.
  • No shares sold: According to the filing, the reporting person did not sell any of the ordinary shares acquired upon the exercise.
  • Direct ownership after transaction: Following the exercise, Gonen directly holds 66,019 ordinary shares in Table I.
  • Warrant expiration: The Series A Warrants exercised were exercisable from November 28, 2022, through November 28, 2026, and now show 0 derivative securities remaining.
  • Additional indirect holdings: The filing also reports 11,784, 8,500, and 8,900 ordinary shares held indirectly, representing unvested RSU grants from February 2024, February 2025, and March 2026, respectively.
  • Stock options on record: Five stock option grants covering a total of 404,987 ordinary shares are reported for informational purposes, with no transactions affecting those holdings.

MediWound CEO Warrant Exercise and Beneficial Ownership Details

According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 12, 2026, Ofer Gonen, Chief Executive Officer of MediWound Ltd. (NASDAQ:MDWD), exercised Series A Warrants on November 10, 2026, to purchase 8,168 ordinary shares at an exercise price of $13.475 per share. The filing states that the aggregate exercise price was paid in cash, and that "no separate price was paid for the Series A Warrants upon exercise." The reporting person did not dispose of any shares acquired through the exercise.

The filing notes that the directly held total of 66,019 ordinary shares following the transaction also includes 35,714 ordinary shares underlying restricted share units granted on June 7, 2022, which became fully vested on June 7, 2026. Three additional rows in Table I report indirectly held shares consisting of unvested RSUs: 11,784 shares from an RSU grant dated February 26, 2024; 8,500 shares from a grant dated February 11, 2025; and 8,900 shares from a grant dated March 4, 2026. Each of these RSU grants follows a vesting schedule in which 25% vested upon the one-year anniversary of the grant date, with an additional 6.25% vesting quarterly over the following three years.

Table II of the filing lists five stock option grants held directly by Gonen, with exercise prices ranging from $11.885 to $18.54 per share and expiration dates between June 7, 2032, and March 4, 2036. The filing states that "there were no transactions affected in respect of the securities reported" in those rows, and they are "included for informational purposes only." The Series A Warrants, which had been exercisable since November 28, 2022, now show a remaining balance of 0 following the November 10, 2026, exercise.

What Was Disclosed

Ofer Gonen, CEO of MediWound Ltd., reported the exercise of 8,168 Series A Warrants at $13.475 per share on November 10, 2026, with no shares sold. The filing also disclosed RSU holdings and five informational stock option grants, all held directly or indirectly.